Enter assignee name

EPO Patents = 1

Trademarks = 19

Forward Citations = 3

Loading Chart...

9 inventors (with patents filed for the assignee):

Mark Mitchnick (5 out of 43 patents)

David F Hale (5 out of 12 patents)

Edward T Maggio (5 out of 52 patents)

4. Steve Cartt (5 out of 13 patents)

5. David Medeiros (5 out of 8 patents)

6. Garry Thomas Gwozdz (5 out of 19 patents)

7. Andrew Loxley (3 out of 3 patents)

8. Andrew L Loxley (2 out of 54 patents)

9. Stuart Madden (1 out of 1 patent)

6 patents: Sort by Forward Citations

1. 12337061 - Administration of benzodiazepine compositions (2025-06-24),

2. 12324852 - Administration of benzodiazepine compositions (2025-06-10),

3. 12268664 - Administration of benzodiazepine compositions (2025-04-08),

4. 12171868 - Intranasal olanzapine formulations and methods of their use (2024-12-24),

5. 11793786 - Administration of benzodiazepine compositions (2023-10-24),

6. 11241414 - Administration of benzodiazepine compositions (2022-02-08),

Neurelis, Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of central nervous system disorders. The company aims to address unmet medical needs through its proprietary drug delivery technologies and formulations. Neurelis is committed to improving the lives of patients by providing effective and safe treatment options. Their lead product candidate is designed to offer rapid and effective relief for patients experiencing seizures. With a strong emphasis on research and development, Neurelis collaborates with healthcare professionals and researchers to advance its pipeline and bring new therapies to market.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

6 Patents

#734 in San Diego, CA

#10,295 in California

#43,803 in US

San Diego, CA, United States of America

Neurelis, Inc.